
|Videos|April 12, 2022
What’s next for sacral neuromodulation in OAB patients with Parkinson’s disease?
Author(s)Urology Times staff
“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.
Advertisement
In this video, Sarah Martin, DO, discusses the take-home message from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5


















